Informations générales (source: ClinicalTrials.gov)
Predictive Value of FDG-TEP During Exclusive Chemo-Radiotherapy (CRT) in Patients With Oesophageal Carcinoma Cancer on the One-Year Survival (RTEP3) (RTEP3)
Observational
Centre Henri Becquerel (Voir sur ClinicalTrials)
mai 2009
avril 2014
29 juin 2024
The poor prognosis in the early-stage of oesophageal carcinoma cancer is due to potential
worsening of the disease (local relapse, metastasis), to insufficient efficacy and
toxicity of actual treatments.
FDG-PET is a medical imaging modality allowing the quantification of the tumour glucose
consumption. Then, this exam is used for pathology staging, target volume definition for
RT, and treatment efficiency few months after CRT. Our assumption is that an FDG-PET exam
during the course of CRT might be predictive of the treatment efficiency few months
later.
In this study, we propose to perform 4 FDG-PET: first "PET1" before chemo-radiotherapy,
second "PET2" during the chemo-radiotherapy (see RTEP1), third and fourth "PET3" "PET4"
3month and 12 month after the end of radiotherapy.
We will investigate the performances of FDG-PET performed during CRT for the prediction
of the one-year patient heath outcome. If the predictive value of TEP2 is confirmed, we
would be able to optimize the planning treatment during the course of the therapy.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC H.Becquerel - 76000 - Rouen - Haute Normandie - France | THILLAYS Marc, RT | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Carcinoma épidermoïde of the oesophagus histologically proved, UICC Stage II B, III
or IVa (TNM on 2002)
- Decision of treatment by radio concomitant chemotherapy (radiotherapy in classic
spreading of 50Gy associated with a platinum chemotherapy.
- Carcinoma épidermoïde of the oesophagus histologically proved, UICC Stage II B, III
or IVa (TNM on 2002)
- Decision of treatment by radio concomitant chemotherapy (radiotherapy in classic
spreading of 50Gy associated with a platinum chemotherapy.
- Presence of a second evolutionary cancer in the previous three years
- index of performance OMS > 2
- Patients badly balanced diabetics